IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

This Comment is linked to The Lancet Haematology Series on Sexual Health in Patients with Haematological Malignancies; we ...

The hand sanitizer spray pen market is projected to grow at a CAGR of 11% over the forecast period, reaching a market value ...

On Wednesday, a jury in Cook County Circuit Court in Illinois ended in a mistrial in a case against Zantac manufacturer ...

GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed ...

Seven independent members of the company’s board resigned Tuesday, concluding that despite co-founder and CEO Anne Wojcicki’s ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Head and Neck Cancer ...

A group of lawmakers wants the U.S. Patent & Trademark Office and drug companies to change their approach toward handling ...

Axial Spondyloarthritis (axSpA) is a form of arthritis that mainly causes discomfort and inflammation in the spine and ...

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.